2 weeks Ago By ABMN Staff
Lynx1 Capital Management LP purchased a new stake in Kiniksa Pharmaceuticals, Ltd. ( NASDAQ:KNSA – Free Report ) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 9,500 shares of the company’s stock, valued at approximately $177,000.
Kiniksa Pharmaceuticals makes up approximately 0.1% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 14th largest holding. Other hedge funds also recently made changes to their positions in the company.
Millennium Management LLC grew its stake in shares of Kiniksa Pharmaceuticals by 159.8% during the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after buying an additional 382,539 shares during the last quarter.
Squarepoint Ops LLC increased its holdings in Kiniksa Pharmaceuticals by 84.0% in the 2nd quarter. Squarepoint Ops LLC now owns 24,845 shares of the company’s stock worth $464,000 after purchasing an additional 11,344 shares in the last quarter.
Rubric Capital Management LP increased its holdings in Kiniksa Pharmaceuticals by 10.2% in the 2nd quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after purchasing an additional 223,094 shares in the last quarter.
XTX Topco Ltd bought a new position in Kiniksa Pharmaceuticals in the second quarter valued at about $314,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Kiniksa Pharmaceuticals by 31.2% during the second quarter.
Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after purchasing an additional 157,741 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.
Kiniksa Pharmaceuticals Stock Down 0.6 % KNSA opened at $23.96 on Friday.
Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $14.12 and a twelve month high of $27.
92. The company has a fifty day moving average of $25.41 and a 200-day moving average of $21.
33. The stock has a market cap of $1.71 billion, a PE ratio of 217.
84 and a beta of 0.33. Insider Buying and Selling at Kiniksa Pharmaceuticals In other news, CFO Mark Ragosa sold 24,248 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, July 23rd.
The shares were sold at an average price of $24.79, for a total value of $601,107.92.
Following the completion of the sale, the chief financial officer now owns 19,253 shares in the company, valued at approximately $477,281.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink .
In related news, CFO Mark Ragosa sold 24,248 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $24.79, for a total value of $601,107.
92. Following the completion of the sale, the chief financial officer now directly owns 19,253 shares of the company’s stock, valued at approximately $477,281.87.
The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link . Also, insider John F. Paolini sold 22,000 shares of the stock in a transaction that occurred on Tuesday, July 23rd.
The stock was sold at an average price of $26.32, for a total value of $579,040.00.
Following the completion of the transaction, the insider now owns 47,803 shares in the company, valued at approximately $1,258,174.96. The disclosure for this sale can be found here .
Over the last three months, insiders have sold 278,064 shares of company stock valued at $7,165,254. 54.57% of the stock is currently owned by company insiders.
Analyst Ratings Changes Several research firms recently commented on KNSA. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.
00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group began coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a “buy” rating and a $40.
00 price objective for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $33.
60. View Our Latest Analysis on KNSA About Kiniksa Pharmaceuticals ( Free Report ) Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Featured Articles Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
